✦ LIBER ✦

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

✍ Scribed by Carsten Bokemeyer; Eric Van Cutsem; Philippe Rougier; Fortunato Ciardiello; Steffen Heeger; Michael Schlichting; Ilhan Celik; Claus-Henning Köhne

Book ID: 116431078
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 504 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.02.057

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Economic analysis of bevacizumab, cetuxi

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB

6079 Overall survival of patients with K

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

✍ Bokemeyer, C.; Bondarenko, I.; Hartmann, J.T.; DeBraud, F.; Schuch, G.; Zubel, A 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Intermittent chemotherapy plus either in

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

✍ Wasan, Harpreet; Meade, Angela M; Adams, Richard; Wilson, Richard; Pugh, Cheryl; 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 442 KB

No Survival Benefit from Adding Cetuxima

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

✍ Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yan 📂 Article 📅 2012 🏛 Public Library of Science 🌐 English ⚖ 533 KB

Magnitude of benefit of the addition of

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

✍ Fotios Loupakis, Emilio Bria, Vanja Vaccaro… 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 544 KB

Addition of cetuximab to oxaliplatin-bas

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

✍ Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 364 KB